Divi's Laboratories Overview
- Founded
-
1990
- Status
-
Public
- Employees
-
16,543
- Stock Symbol
-
DIVISLAB
- Share Price
-
$41.59
- (As of Friday Closing)
Divi's Laboratories General Information
Description
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. Most of the company's sales are generated in Europe, followed by North America, India, and Asia. Divi operates two segments: the first is Generic APIs and Nutraceuticals, and the second is Custom Synthesis of APIs, intermediates, and specialty ingredients for innovators. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NSE
Primary Office
- Divi Towers, Cyber Hills
- Gachibowli
- Hyderabad, 500032
- India
+91 040 0000 0000
Divi's Laboratories Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $41.59 | $40.88 | $39.48 - $61.12 | $10.9B | 265M | 531K | $1.47 |
Divi's Laboratories Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | 11,710,596 | 15,157,748 | 12,841,908 | 6,921,067 |
| Revenue | 1,166,970 | 1,180,985 | 921,821 | 744,706 |
| EBITDA | 499,790 | 526,983 | 385,052 | 282,135 |
| Net Income | 389,742 | 397,336 | 266,706 | 193,741 |
| Total Assets | 1,659,067 | 1,763,815 | 1,466,942 | 1,131,755 |
| Total Debt | 405 | 487 | 658 | 5,151 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Divi's Laboratories Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Divi's Laboratories Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Divi's Laboratories Ltd is a specialty and generic drug manufacturing company. Most of the company's sales are generated
Drug Discovery
Hyderabad, India
16,543
As of 2022
00.000
000000000
00.000
00000
t esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat
000000000000000
Ahmedabad, India
00000
As of 0000
000.00
0000
0000-00-00
00000000
000.00
000000
nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qu
000000000000000
Tokyo, Japan
00000
As of 0000
00000000
Add Comparison
Divi's Laboratories Competitors (13)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Zydus Lifesciences | Corporation | Ahmedabad, India | 00000 | 000.00 | 00000000 | 000.00 |
| 00000000 000000 | Corporation | Tokyo, Japan | 00000 | 00000000 | ||
| 000000000 000000 | Corporation | Hyderabad, India | 00000 | 00000 | 000000000 | 00000 |
| 000000000 | Corporation | Mumbai, India | 0000 | 000000000 | ||
| 00000 000000000000 | Private Equity-Backed | Ahmedabad, India | 00000 | 000.00 | 00000000000 | 000.00 |
Divi's Laboratories Patents
Divi's Laboratories Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4079746-A1 | Process for the preparation of molnupiravir | Pending | 23-Apr-2021 | 0000000000 | 0 |
| JP-2022167736-A | Method for manufacturing molnupiravir | Pending | 23-Apr-2021 | 0000000000 | |
| US-11407779-B1 | Process for the preparation of molnupiravir | Active | 23-Apr-2021 | 00000000 | 0 |
| EP-4036244-A1 | Enzymatic process for the preparation of (2s)-2-[(4r)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam | Pending | 01-Feb-2021 | 000000000 | 0 |
| JP-2022117945-A | Enzymatic process for preparation of (2s)-2-[(4r)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and conversion to brivaracetam thereof | Pending | 01-Feb-2021 | C12P17/10 |
Divi's Laboratories Executive Team (4)
Divi's Laboratories Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| 00000000 0000 | Divi's Laboratories | Board Member | 000 0000 |
| 0000000 0000000000 | Divi's Laboratories | Board Member | 000 0000 |
| 00000000000 0000 | Divi's Laboratories | Board Member & Executive | 000 0000 |
| 000000 0000 00.0 | Divi's Laboratories | Board Member & Founder | 000 0000 |
| 000000 0000 | Divi's Laboratories | Board Member & Executive | 000 0000 |
Divi's Laboratories Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Divi's Laboratories Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Divi's Laboratories ESG
Risk Overview
Risk Rating
Updated March, 07, 2022
17.86 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,613
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,004
Rank
0.00
Percentile
Laboratory Equipment and Services
Subindustry
00 of 70
Rank
00.0
Percentile
